clinical trial · NCT05852431
To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia
89bio, Inc.·phase3·active not recruiting·n = 360
Severe HypertriglyceridemiaPegozaferminPlacebo
brief summary
To determine the effect of Pegozafermin on fasting serum triglyceride levels in subjects with Severe Hypertriglyceridemia (TG ≥500 to ≤2000 mg/dL) after 26 weeks of treatment.
started
Jun 15, 2023
primary completion
Jul 7, 2025
completion
Apr 1, 2026
last updated
Aug 7, 2025
official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia (SHTG): The ENTRUST Study
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol